The concepts that require validation in terms of the subject of endocrine disruption are listed and discussed. The main mechanisms by which endocrine disruption can occur are identified, and the assays required for the detection of adverse endocrine disruption toxicities associated with these mechanisms are discussed. The process of assay validation is considered. The validation of structureactivity relationships, the need for reference chemicals, and the problems recently encountered when attempting to reproduce endocrine disruption data are also explored. The most important conclusions derived from this analysis are that given the immature state of research into endocrine disruption toxicity, testing strategies and the types of assay employed should be kept under constant review; inevitably researchers need to accept the fact that future revision of each assay will be required. Second, given the current absence of any chemical that is universally accepted to be devoid of endocrine toxicity, assay specificity will be difficult to assess, and that imposes the need for alternative objective criteria for assessing the value of individual assays.
INTRODUCTION
The word validation implies the need to ensure that an article/assumption is sound, genuine, logical, satisfactory, authoritative, and convincing. These terms provide a good starting point for this chapter, but they are without meaning in the absence of a description of that which is to be validated. At the simplest level, the perception is that some environmental chemicals may be capable of disturbing the endocrine system of animals, in turn leading to adverse reproductive or developmental outcomes, and that this potential to disturb can be assessed using a few standard assays that require only minimal validation before they can be routinely deployed. In fact, the issue in question is highly complex, and a range of distinct validation needs are evident. At the most fundamental level there is a need to validate the basic assumption that the reproductive capacity and sexual development of humans and/or wildlife species have already been (or in future might be) compromised by ambient levels of exposure to endocrine disrupting (ED) chemicals. Certain adverse human and wildlife effects have been associated with chemical exposures, but proof of causation usually remains for study. The validation process required to transform ED associations into ED causations has been discussed (5) within the context of the hypothesis-testing criteria of Hill (18) . This critical validation need is not pursued further herein because causation has already been assumed by a sufficient number of regulatory authorities to require the development of assays for ED activities and the formulation of testing strategies/legislative testing guidelines.
Once it is assumed that some environmental chemicals may present a hazard to the endocrine system of one or more organisms, several additional requirements present themselves. The most important of these is the need to devise and validate a testing framework that will include assays to cover the several possible mechanisms by which chemically induced reproductive or sexual development toxicities can be produced. At present these assays fall into 4 major classes, as follows: (a) In vitro assays that determine the ability of an agent to interact with natural hormone receptors; (b) In vivo assays to measure disturbances to the normal biochemical synthesis and degradation of the natural steroid hormones; (c) Assays to determine adverse ED effects in mammals; and (d) Additional tests using wildlife species, as individually considered appropriate (see further discussion under Testing Strategies).
Validation of the final list of assays will involve the collection of test data to justify the inclusion or exclusion of individual assays and agreement on the types of organisms to be monitored. In addition, the assays selected for routine use will need to be validated in order to establish that they are sensitive to reference endocrine disruptors operating by the appropriate mechanism and to confirm that they are practical to conduct and that they give reproducible test data within and between laboratories. This last validation &dquo;need&dquo; requires the existence of a library of reference chemicals known to possess the adverse ED activities being predicted together with agents known to be inactive in these respects.
At this point it is relevant to note that the above approach to validation could have been usefully applied to the study of environmental carcinogens. However, in that endeavor, several mistakes were made: (a) The risk posed to humans by exposure to animal carcinogens was assumed and not proven, and this risk has since been seriously questioned. A range of different testing strategies FIGURE 1.-Biosynthesis of natural hormones affecting the estrogen receptor (ER), the androgen receptor (AR), and the thyroid hormone receptor (THR) and chemicals known, or predicted, to modify these normal functions. TSH = thyroid stimulating hormone; PTU = 6-propylthiouracil ; PCB = polychlorinated biphenyl. were applied retrospectively, and then only when it was realized that different countries were employing different predictive assays, usually for different purposes. And (b), chemical carcinogenicity was initially assumed to represent a singular property of chemicals. That led to a fruitless search for a single &dquo;wonder assay&dquo; for use with all possible types of rodent/human carcinogens. Further, evaluation of the practicality and reproducibility of assays was left until a late stage, at which point many unreliable/ unjustified assays had been incorporated into the regulatory guidelines of some countries. In the prediction of endocrine disrupters, a repetition of these same mistakes can only be avoided by adherence to an internationally agreed-upon validation process.
MECHANISMS OF ED
The several mechanisms by which endocrine disruption may occur will ultimately dictate the types of assay required for the detection/assessment of ED chemicals (see Testing Strategies). The mechanisms currently being considered by the US Environmental Protection Agency Endocrine Disruptor Screening and Testing Advisory Committee (EDSTAC) (2) are represented in Figure 1 .
These mechanisms include either disturbance of the biochemical production and/or destruction of the natural hormones estradiol, dihydrotestosterone, and triiodothyroxine or competitive agonist/antagonist activities of xenobiotic chemicals at the naturally occurring receptors for these hormones (the estrogen receptor [ER], the androgen receptor [AR], and the thyroid hormone receptor [THR], respectively). To date, the most attention and the most data have been concerned with ER agonists and AR antagonists, but there is general agreement that these are but two of several potential mechanisms of ED toxicity. There is an essentially endless list of possible ways of altering the biochemical production/destruction/homeostasis of the 3 natural hormones under consideration, but available evidence only supports this concern for the in-hibition of either dihydrotestosterone or estradiol production (eg, by inhibition of the cytochrome P-450 enzymes 5cx-reductase and aromatase, respectively; see Figure 1 ). Concerns regarding the disturbance of thyroid gland function are less well defined, but they are based on the antithyroid (hypothyroid) activities of 6-propylthiourea and the polychlorinated biphenyls (PCBs), each activity leading to increased testis size in treated rodents (15, 17) . These and other possible ways in which disturbance of the normal functioning of the thyroid gland could be induced are shown in Figure 1 . It is noticeable that to date, no ED activities have been associated with THR agonists/ antagonists, with hyperthyroid chemicals, or with agents capable of inhibiting iodinase enzymes (responsible for the conversion of T~ to T3 in the liver).
The extent to which these many activities of chemicals can be assessed using in vitro assays will need to be carefully considered and validated. On the one hand, receptor-mediated effects seem optimal for assessment using appropriate in vitro assays (particularly when such assays are made to be metabolically competent); in contrast, disturbances in steroidogenesis and thyroid gland function would seem best suited to evaluation in the whole organism. It is critical that the difference between an activity (eg, ER binding, enzyme inhibition) and an adverse toxicity (eg, reduced testes size, increased day of vaginal opening) be carefully distinguished when attempting to validate assays, in particular those conducted in vitro.
When considering hormone receptor-mediated ED toxicities, there are 4 main receptors currently under consideration : ERa, ERr3 (23, 24) , AR, and THR. In addition, there are 2 ways in which the normal functioning of these receptors in their natural environment can be modified-through competitive receptor agonism and receptor antagonism (Figure 1 ). These 8 points of endocrine disturbance currently suggest the need for 8 separate assays. The following points, however, argue against this and indicate the need for a constant review of the assays that are actually required. First, the assumed discrete nature of ER/AR agonist/antagonist properties of chemicals underlies the EDSTAC proposal to monitor these activities separately for each chemical (2) . However, the knowledge base supporting this quadrupling of testing effort is thin and is often not supportive. For example, the simple model assumed by the current ED-STAC approach is that some chemicals will act as either pure agonists or pure antagonists solely as a function of their chemical structures. An alternative prospect, one with very different implications for testing, is that interaction of a chemical with ER is the only useful thing that can be discerned in vitro, with the study of agonist/antagonist effects only being approachable in intact organisms. Supporting this proposition, Horwitz (19) has reviewed the range of ER-related responses elicited by tamoxifen in humans and has shown that they are dependent upon the tissue being monitored and the duration of dosing. Similar conclusions apply to the selective estrogen raloxifene (10, 16, 36) . Further, Willson et al (35) have shown that GW5638, an ER antagonist in vitro and in the rat uterus in vivo, acts as a full ER agonist in the rat bone and cardiovascular system. Such subtle responses indicate that receptor agonist/antagonist activities are not a function of the chemical structure of an agent but rather are a function of the receptor response element and/or the tissue under study (ie, these are toxicodynamic and pharmacodynamic issues). If this is true, the critical need becomes the study of how chemicals interact with ER/AR in a range of different genetic and/or tissue environments (20) . Despite these concerns, the current concept that receptor agonist/antagonist effects reflect intrinsic properties of chemicals (as opposed to biological environments) is maintained. The further complexity engendered by the recent recognition of 2 forms of the ER (23), the tissue-and chemical-specific responses of these receptors (24) , and the recognition that several estrogens can also function as antiandrogens (33) will inevitably complicate this matter further; thus, there is a need for constant review (validation) of ED assays and testing strategies.
THE PROCESS OF ASSAY VALIDATION
The process to be followed when validating a test method has been discussed in detail by Ball and Karcher (9) , based on the conclusions of a series of workshops. The advice given is particularly relevant to the validation of ED assays, and the essence of that advice is endorsed and reproduced here.
Five main stages in the evolution of new test methods were identified: test development (in laboratory of origin), prevalidation (involving an informal interlaboratory study), validation (involving a formal interlaboratory study), independent assessment (of study and proposals), and progression toward regulatory acceptance.
Test Development
It was suggested that the following criteria be met before a method is considered to be ready to enter the validation process: a description of the basis of the method coupled with a clear specification of endpoint, endpoint measurement, derivation, and expression of results and their interpretation and application should be provided.
A definition of the scientific purpose of the method should be provided. The case for its relevance and its proposed practical application should be made. An explanation of the need for the method in relation to type and extent of effects, levels of assessment, and availability of other methods should be provided. The availability of an optimized protocol with standard operating procedures, including use of adequate control groups, should be assured. A clear statement about the limitations of the method should be provided. And finally, evidence of intralaboratory reproducibility and of interlaboratory transferability should be offered.
Prevalidation
The proposed prevalidation scheme involves collaboration between established and competent laboratories, as follows: Phase I: protocol refinement; Phase II: protocol transfer; and Phase III: protocol performance.
Validation/Independent Assessment
The criteria for evaluating a validation study were suggested to include consideration of the following: clarity of defined goals; quality of overall design; independence of management; independence of selection, coding, and distribution of test materials; independence of data collection and analysis; number and properties of test materials studied; quality of interpretation of results; performance of methods in relation to goals of the study; reporting of outcome in the peer-review literature; availability of raw data; and independence of assessment of outcome.
These are stringent requirements that cannot easily be circumvented without prejudicing attempts to rapidly develop reliable assays for endocrine disruption.
TEST ORGANISMS
The need to study both humans and wildlife species has been recognized from the outset (13, 25) . The study of human effects is best conducted in humans; however, as in other branches of toxicology, laboratory species such as the rat and the mouse will be employed as human surrogates. In contrast, the extent to which rodent data can be used to anticipate possible ED effects in all wildlife species has yet to be resolved. The limited data available indicate that ED hazards to wild mammals can be predicted using the approach adopted for human hazard assessment, but invertebrate, avian, and fish species may not always be covered by this approach. Recent reviews (1, 12) have considered this topic in detail, including suggestions as to which sentinel wildlife species would be most appropriate for use. Perhaps the most important point raised in those reviews had to do with the current paucity of knowledge related to the working of the endocrine system of most wildlife species-in particular, of invertebrates (1). In practice, this means that assessment of nonmammalian ED effects will be extremely difficult in the immediate future, and in this area, the concept of validation will be concerned more with the selection and study of sentinel species than with the sensitivity and performance of assays based on those species.
STRUCTURE-ACTIVITY RELATIONSHIPS
Different structure-activity relationships (SARs) will be required for each mechanism of ED; there will be no general SAR of ED. The only qualification to this is that there is growing evidence of an overlap between receptors ; thus, SAR for ER may have some implications for the SAR of AR, etc. The validation of SAR in ED will therefore require a clear definition of the mechanism of ED involved and specific clarification of the level of biological data being considered. For example, the SAR of ER binding in vitro will be different from the SAR of activity in a rodent uterotrophic assay, despite the fact that the latter assay monitors ER activity and the fact the former assay is predictive of activity in the latter assay. Structure-activity relationships for the ER are discussed below to illustrate the potential complexity of what is often regarded as the simplest of predictive assays. Structure-activity relationships for ER interactions are currently anchored to the chemical structure of estradiol (Ez) itself (11) and to the manner of its interaction with the ER. Thus, the molecular shape of E, enables the estrogenic activity of the &dquo;look-alike&dquo; hydroxylated PCBs to be estimated (14) . However, Connor et al (14) concluded the following: &dquo;structure-estrogenicity/antiestrogenicity relationships for the eight compounds studied were complex and response-specific. The structure-ER binding relationships were different in the rat and the mouse, and no dose-dependent estrogenic activities were observed in the rat or mouse uterus. Several compounds exhibited antiestrogenic activity and two inhibited progesterone receptor (PR) binding in the mouse uterus.&dquo; This complex picture is further confused by our recent finding that estratriene (E2 with both of its -OH groups removed) is a potent estrogen both in vitro and in vivo (J. Ashby and J. R Sumpter, unpublished data). This complexity indicates that computerized structural databases based on the chemical structure of the sex hormones may alert us to obvious structural analogues, but at present, they will be unable to venture into the area of real need, the prediction of activity for structurally remote analogues of E2 (eg, kepone and dieldrin) or of testosterone (eg, vinclozolin) (21, 22) .
REFERENCE CHEMICALS
Assessment of assay sensitivity and specificity requires access to established ED agents and to agents that are agreed to be devoid of ED activities. The composition of these 2 groups of chemicals has yet to be agreed upon.
Reference ED Agents
The tabulation of known ED active chemicals is an easier task, but one that is not without its own problems. To the extent that a set of genuinely distinct mechanisms of ED toxicity exist (eg, interaction with the ER), it should be possible to select representative chemicals for each mechanism for validation of the appropriate assay. Using the same example, the problem immediately encountered with this approach is that although many chemicals are known to interact with ERs in vitro, the number of these that have produced sentinel ER-mediated toxicities in animals or wildlife species is limited. For example, despite the fact that many studies have established the capability of bisphenol A (BPA) to produce effects associated with its interaction with ER in vitro, it is difficult to identify confirmed toxicities that are causally aligned with this property-a critical distinction. An analogy derived from carcinogen screening experience is that some in vitro assays that found noncarcinogens to be positive tended to be justified by reference to activities that were found to be similar for the chemical in question in other in vitro assays-a dangerous cyclic process. This problem was discussed by Gina Solomon during a recent US EDSTAC meeting, as reported by EndocrinelEstrogen Letter (2): &dquo;if you require that something has to have an adverse effect before labelling it as an endocrine disruptor, then you are shifting the level of scientific proof needed to a very high level. It is not hard to show that something mimics estrogen, but to show that it also causes an adverse effect is surprisingly tricky.&dquo; That dilemma is probably the most serious one that we face at present. Sentinel chemicals representing different mechanisms of endocrine disruption. These agents are suggested to be suitable for the initial validation of ED assays. Documentation of the adverse properties of these chemicals will be necessary before they are adopted.
An initial list of calibrant ED chemicals is suggested
in Table 1 , which is based on the mechanisms of ED toxicity illustrated in Figure 1 . There is adequate evidence that these chemicals produce adverse ED-mediated toxicities in vivo, but those data still need to be documented, as described above. The agents shown in Table   1 do not include those chemicals that may be capable of affecting uniquely invertebrate endocrine systems. The number of chemicals capable of disturbing thyroid gland function is currently limited to the 2 agents shown in Table 1 [6-thiouracil and PCB s, both of which increase testis weight in rats (15, 17) ].
Agents Devoid of ED Activities
At present there are few, if any, agents generally agreed to have no ED activities, and this is attributable to the current absence of chemicals classified as negative in a rodent multigeneration study conducted according to a protocol that includes the recently recommended additional markers of sexual development. As a consequence, assessment of the specificity of ED assays will be difficult in the immediate future. Nonetheless, the need for such data in the assessment of newly derived assays cannot be overemphasized. In the absence of such agents, the response given to a chemical by a new ED assay will not be predictive of activity but rather will be definitive of activity (no false-positive predictions having been shown for the assay). For example, it is often stated at conferences that the MCF7 assay (the E-screen) has given no false-positive responses to date, which is a meaningless statement in the absence of named chemicals that are inactive as endocrine disruptors.
LISTS OF ED AGENTS
In order to be legitimately listed as an ED agent, it is necessary that the chemical has been shown to disrupt an endocrine system, and that implies the availability of test data from an organism with an intact endocrine system. In the absence of such data, potential ED agents may be added to lists of estrogens, androgens, or progestins, for example, based on their ability to bind to the appropriate isolated receptor. The latter lists will be of little toxicologic value, but they will be valuable for prioritizing agents for further study. The illusory value of lists of chemicals has recently been documented by Scialli (28) in an article of immediate relevance to endocrine disruptors-&dquo;Identifying Teratogens: The Tyranny of Lists.&dquo;
REPRODUCIBILITY OF ED DATA The many problems encountered when attempting to confirm independently reported ED effects have been commented on earlier (4) , and these problems can be expected to present a continuing challenge to all investigators in this field. This is primarily because the possible activities under study encompass virtually the whole of biology-few biological functions being totally independent of gender status and the degree of sexual development or senescence of the organism under study. Thus, a chemical may alter the body weight of a developing animal, thereby leading to a change in the timing of sexual maturation, and in such situations, it will be difficult to associate the sexual change with either the body weight change or with any intrinsic ED activities that the chemical may possess. A related example is the demonstration by Steinmetz et al (34) that both E2 and BPA are able to increase plasma prolactin levels in Fischer 344 rats but not in Sprague-Dawley rats. It is easy to imagine the results from these 2 strains of rat being separately derived and reported, thereby leading to the impression of a conflict between laboratories and investigators. It also remains possible that a subtle difference between substrains of Wistar rats may be at the root of the failure to replicate the ability of butyl benzyl phthalate (BBP) to reduce testis size in rats (7, 29) . Adding to this potential complexity is the fact that little is currently known about many of the biological processes currently being implicitly investigated in ED research. For example, Shull et al (31 ) have shown that ACI rats develop mammary gland cancer upon exposure to E2, leading to the expectation that ovariectomized ACI rats that were exposed to the same net plasma concentrations of E, experienced in the treated intact animals would develop a similar incidence of mammary gland tumors. In fact, the ovariectomized animals were resistant to the carcinogenicity of estradiol. This finding led Shull et al (31 ) to consider the complementary role of progesterone in estradiol-induced mammary gland carcinogenesis. The significance of these results lies in the fact that ovariectomy would hitherto have been considered to represent a potentially useful model for studying the effects of xenobiotic estrogens on the rodent mammary gland-yet this is clearly not the case. Examples such as these illustrate that current attempts to study endocrine disruption are being made against a background of significant ignorance regarding many of the fundamental aspects of endocrine homeostasis. Such ignorance should not disable attempts to make progress in this field but rather should signal caution when suggesting testing strategies and regulatory testing requirements.
TESTING STRATEGIES
The development of practical and validated assays for ED effects is presently the subject of intensive intema-tional research, and within that context, the acceptance by EDSTAC of the fact that some of their preferred assays are only at the research stage of development as well as the redundancy evident among the assays they listed confirms that this field is in a state of infancy. This situation indicates that the most efficient way to proceed is to use the few currently available assays in a hierarchical way (3, 27) and to keep under constant review the findings of current research. Thus, one suggested approach (30) is to gather data on the activity of major chemicals (of unknown reproductive toxicity) in in vitro assays for the expression of transfected ER and AR and to study further any active compounds in the available mammalian and wildlife ED assays. This will be an imperfect and temporary approach. For example, it may be that some ER agonists found to be inactive in the rodent uterotrophic assay may eventually be shown to exert a subtle but important effect on the rodent prostate gland, or we may find that an agent may exert a specific ED effect in birds after having been defined as inactive in trout. Such findings could lead to a revision of the testing strategy. However, the alternative (precautionary) of seeking a perfect testing strategy using only the currently available assays may present greater eventual problems than those encountered with an evolutionary approach. The consensus represented by the International Program of Chemical Safety (IPCS) scheme for using short-term mutagenicity assays to predict carcinogens and germ cell mutagens (8) illustrates that an hierarchical approach to testing is a realistic prospect, although certainly many compromises were required between those participants who were influenced primarily by precedents and those who were influenced primarily by possibilities. The final IPCS consensus was mediated by the decision that proponents of the inclusion of a particular assay would be required to name one mutagen/carcinogen that would remain undetected if it were to be omitted from the scheme. A similar requirement would help to justify the final battery of ED assays accepted by regulatory authorities. The large number of toxicological considerations relevant to the design of an efficient ED testing strategy have been discussed elsewhere (3).
DOSE LEVEL SELECTION
It has been suggested by several investigators that the selection of dose levels for whole-animal ED studies will require a different approach to that adopted in other branches of toxicology. The examples cited include the plasticizer BBP, which has a no-effect level for rat liver enzyme induction (and an associated anticarcinogenic effect in the rat mammary gland) of about 250 mg/kg body weight (32), although it is reported to increase the weight of rat testis at a dose that is 1,000 times lower (29) . Likewise, Nagel et al (26) have discussed presumed ED activities of BPA occurring at dose levels that were orders of magnitude lower than those required to produce activity in the rat uterotrophic assay (6) . The reality and implications of such effects for dose setting in ED studies require urgent and objective evaluation/validation before changes are made to the usual criteria for dose selection.
